NGM NGM Biopharmaceuticals Inc.

14.9
-0.39  -3%
Previous Close 15.29
Open 15.29
Price To Book 2.84
Market Cap 984,040,193
Shares 66,042,966
Volume 128,746
Short Ratio
Av. Daily Volume 110,004

NewsSee all news

  1. NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results
  2. Weekly Top Insider Buys Highlight for the Week of July 19
  3. How Much Are NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Insiders Spending On Buying Shares?
  4. NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
  5. NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1a/1b trial to be initiated 2H 2019.
NGM120
Cachexia syndrome
Phase 2 trial to be initiated 2020.
NGM313 / MK-3655
Non-alcoholic steatohepatitis (NASH) and Type 2 diabetes
Phase 1 trial initiated 2Q 2019.
NGM621
Geographic atrophy
Phase 2 interim cohort 4 data 4Q 2019.
NGM282
Non-alcoholic steatohepatitis (NASH)
Phase 2b initial data due by the end of 2020.
NGM282 - ALPINE 2/3
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results
  2. Weekly Top Insider Buys Highlight for the Week of July 19
  3. How Much Are NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Insiders Spending On Buying Shares?
  4. NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
  5. NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association
  6. NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
  7. The Funded: 10 Bay Area startups disclose over $175M in funding at week's end
  8. NGM Bio Announces Pricing of Initial Public Offering
  9. IPO Outlook For The Week: Ruhnn, Silk Road Medical, NGM Biopharmaceuticals And A Trading Platform
  10. TPI Composites- Blowing in the Wind